Anti-cholesterol drug Praluent cuts death risk

March 10, 2018 by Kerry Sheridan
The anti-cholesterol drug Praluent is approved in more than 60 countries outside the US, according to France's Sanofi Pharmaceuticals

The anti-cholesterol drug Praluent (alirocumab), made by France's Sanofi Pharmaceuticals, is linked to a 15 percent lower risk of major cardiovascular events like heart attack and stroke, a study said Saturday.

Alirocumab was also associated with a 15 percent reduction in death from any cause, marking the first evidence that this relatively new class of drugs, called PCSK9 inhibitors, can extend lives.

The benefit was even greater among those with stubbornly high "bad," or LDL cholesterol, above 100 mg/dL. That group saw a 29 percent reduction in death from any cause after taking the drug for two years.

PCSK9 inhibitors are monoclonal antibodies which target and inactivate a specific protein in the liver, dramatically reducing the amount of harmful LDL cholesterol circulating in the bloodstream.

Research has shown these drugs, delivered by injection every two to four weeks, may work even better than statins, which are the traditional first line of treatment for .

High cholesterol is a key factor in , the most common kind of heart disease and the number one killer of men and women worldwide, according to the World Health Organization.

But neither Praluent or its main competitor, Repatha (evolocumab) made by Amgen Pharmaceuticals, has achieved major commercial success due to their hefty annual price tag of more than $14,000 (11,300 euros) per patient.

Last year, researchers reported similar results for Repatha, which also cut the risk of , stroke, and hospitalization for blocked arteries by 15 percent.

"Now that we have two trials that consistently show benefits from PCSK9 inhibitors, and given the mortality benefit that we are reporting here for the first time, I think these results may change the equation for these drugs," said Philippe Gabriel Steg, chief of cardiology at Hopital Bichat in Paris and co-chair of the study.

"We're not just talking about preventing nonfatal events such as heart attacks but actually preserving life."

Cost concerns

The findings described Saturday at the American College of Cardiology conference in Orlando, Florida, were based on an international trial of nearly 19,000 people in 57 countries, randomly assigned to either alirocumab or a placebo.

Those enrolled were over 40 and many had been treated with the maximum amount of statin therapy possible but were still unable to get their cholesterol down.

The trial included those whose LDL cholesterol remained 70 mg/dL or above, non-HDL 100 mg/dL or above.

Participants were followed for up to five years, with 44 percent participating for three years or more.

The injections were well tolerated by patients, with mild itching, redness or swelling at the injection site occurring in about three percent of patients receiving the and two percent getting the placebo.

"I believe this study is going to change practice," said Mount Sinai Medical Hospital's physician-in-chief, Valentin Fuster, who was not involved in the research.

However, he cautioned that drugs' high price remains an obstacle.

"Up until now, the feasibility and affordability of using these types of drugs has been extremely difficult," he told a press briefing.

"I hope this particular study really is a trigger, is a catalyzer, for making these drugs much more available today in people who need it."

Praluent is approved in more than 60 countries outside the US, according to Sanofi, while Repatha was put on the US market in 2015.

In a statement Saturday, Sanofi and Regeneron said they would work to lower the price for patients at high risk.

"We commit to working with all health plans that agree to remove access barriers for high-risk patients to offer a more cost-effective net price for Praluent," said Leonard Schleifer, president and chief executive officer of Regeneron.

Explore further: US court suspends ban on Sanofi, Regeneron cholesterol drug

Related Stories

US court suspends ban on Sanofi, Regeneron cholesterol drug

February 9, 2017
A US appeals court on Wednesday temporarily suspended an order blocking the French pharmaceutical group Sanofi and its American partner Regeneron from selling their anti-cholesterol drug Praluent.

US regulators give limited approval to cholesterol drug

July 25, 2015
US regulators on Friday approved a new cholesterol drug called Praluent, made by Sanofi and Regeneron, for people with certain genetic risk factors for heart disease.

US experts urge approval of another new cholesterol drug (Update)

June 10, 2015
US experts urged regulators Wednesday to approve a second new anti-cholesterol drug, a day after recommending they bring to market the first in a new class of medications to lower the risk of heart attack.

Cholesterol drug cuts heart risks, spurs new debate on cost

March 17, 2017
A long-acting cholesterol medicine cut the risk of having a heart attack or some other serious problems by 15 to 20 percent in a big study that's likely to spur fresh debate about what drugs should cost.

FDA weighs approval of first-in-class cholesterol drug

June 5, 2015
Federal health regulators said Friday that a highly-anticipated, experimental drug from Sanofi lowers bad cholesterol more than older drugs. But officials have questions about whether to approve the drug based on that measure ...

FDA panel backs Amgen cholesterol drug for some patients (Update)

June 10, 2015
Federal health advisers said Wednesday that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance.

Recommended for you

Cardiovascular disease related to type 2 diabetes can be reduced significantly

August 16, 2018
Properly composed treatment and refraining from cigarette consumption can significantly reduce the risk of cardiovascular disease resulting from type 2 diabetes, according to a study published in the New England Journal of ...

Genomic autopsy can help solve unexplained cardiac death

August 15, 2018
Molecular autopsies can reveal genetic risk factors in young people who unexpectedly die, but proper interpretation of the results can be challenging, according to a recent study published in Circulation.

Neonatal pig hearts can heal from heart attack

August 15, 2018
While pigs still cannot fly, researchers have discovered that the hearts of newborn piglets do have one remarkable ability. They can almost completely heal themselves after experimental heart attacks.

Fifty percent of cardiovascular patients suffer from multiple diseases

August 15, 2018
New research led by The University of Western Australia has revealed that one in two patients admitted to hospital with a cardiovascular disease is suffering from multiple chronic medical conditions which required complex ...

Innovative triple pill significantly lowers blood pressure, study finds

August 14, 2018
A new low dose three in one pill to treat hypertension could transform the way high blood pressure is treated around the world.

Drug repurposing study sheds light on heart disease risk

August 14, 2018
A team led by researchers at Brigham and Women's Hospital has developed a computational technique to reveal the unknown side effects—both good and bad—of hundreds of drugs. That knowledge could help pharmacologists discover ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.